EXPERT ADVISORY GROUP REPORTS
- EAG report on ViiV’s dolutegravir for upper-middle-income countries: Azerbaijan, Belarus, Kazakhstan and Malaysia
- EAG report on Pfizer’s sutezolid
- EAG report on Gilead’s bictegravir
- EAG report on AbbVie’s lopinavir, ritonavir for Africa
- EAG report on AbbVie’s LPV/r paediatric
- EAG report on Bristol-Myers Squibb’s daclatasvir
- EAG report on Bristol-Myers Squibb’s atazanavir
- EAG report on the proposed amendments to the MPP-Gilead agreement to incorporate TAF
- EAG report on the Johns Hopkins University’s sutezolid
- EAG report on MSD’s raltegravir paediatric
- EAG report on Pharco’s ravidasvir
- EAG report on the proposed collaboration with Roche
- EAG report on the University of Liverpool’s solid drug nanoparticle technology
- EAG report on ViiV Heathcare’s dolutegravir
- EAG report on the proposed paediatric collaboration with ViiV Heathcare